Zeev Milbauer

Minovia Therapeutics Ltd. is a clinical stage company based in Tirat Carmel, Israel. Minovia Therapeutics is developing a therapeutic platform called mitochondrial augmentation technology (mat) that targets the root cause of diseases generated by mitochondrial dysfunction. The platform enriches patients' hematopoietic stem and progenitor cells with healthy mitochondria isolated from an allogeneic or syngeneic source. The Israeli company's initial clinical focus is on rare mitochondrial diseases for which there are no approved treatments, and the lead product, mnv-201, is composed of autologous hematopoietic stem cells enriched with healthy allogeneic mitochondria. Minovia Therapeutics completed an ind enabled phase i/ii clinical trial in Pearson syndrome, a fatal pediatric disease, and is planning to accelerate the clinical development for Pearson syndrome and expand the pipeline to other hematological/mitochondrial-related diseases. The company was founded in 2012 by Natalie Yivgi-Ohana, Uriel Halavee, Ephraim Aharonson, and Natalie Yivgi-Ohana has been the CEO since 2012.

BioGenCell Ltd. is an Israeli company based at Laniado Hospital in Israel that is dedicated to improving the lives of patients suffering from degenerative microvascular diseases. The company is based in Netanya, Israel. The company aims to extend its reach to address a wider range of vascular and other diseases in the future. BioGenCell has been committed to transforming the lives of patients with degenerative diseases through advanced cell therapy treatments since its inception in 2008. The company's groundbreaking tract technology uses a patient's own blood as personalized medicine. BioGenCell's personalized treatments are produced from the patients' own cells, mimicking the body's natural processes. The company was founded by Michael Belkin, Yael Porat, and Eyal Peleg, and Yael Porat has been the CEO since incorporation.

Minovia Therapeutics Ltd. is a clinical stage company based in Tirat Carmel, Israel. Minovia Therapeutics is developing a therapeutic platform called mitochondrial augmentation technology (mat) that targets the root cause of diseases generated by mitochondrial dysfunction. The platform enriches patients' hematopoietic stem and progenitor cells with healthy mitochondria isolated from an allogeneic or syngeneic source. The Israeli company's initial clinical focus is on rare mitochondrial diseases for which there are no approved treatments, and the lead product, mnv-201, is composed of autologous hematopoietic stem cells enriched with healthy allogeneic mitochondria. Minovia Therapeutics completed an ind enabled phase i/ii clinical trial in Pearson syndrome, a fatal pediatric disease, and is planning to accelerate the clinical development for Pearson syndrome and expand the pipeline to other hematological/mitochondrial-related diseases. The company was founded in 2012 by Natalie Yivgi-Ohana, Uriel Halavee, Ephraim Aharonson, and Natalie Yivgi-Ohana has been the CEO since 2012.

BioGenCell Ltd. is an Israeli company based at Laniado Hospital in Israel that is dedicated to improving the lives of patients suffering from degenerative microvascular diseases. The company is based in Netanya, Israel. The company aims to extend its reach to address a wider range of vascular and other diseases in the future. BioGenCell has been committed to transforming the lives of patients with degenerative diseases through advanced cell therapy treatments since its inception in 2008. The company's groundbreaking tract technology uses a patient's own blood as personalized medicine. BioGenCell's personalized treatments are produced from the patients' own cells, mimicking the body's natural processes. The company was founded by Michael Belkin, Yael Porat, and Eyal Peleg, and Yael Porat has been the CEO since incorporation.

Minovia Therapeutics Ltd. is a clinical stage company based in Tirat Carmel, Israel. Minovia Therapeutics is developing a therapeutic platform called mitochondrial augmentation technology (mat) that targets the root cause of diseases generated by mitochondrial dysfunction. The platform enriches patients' hematopoietic stem and progenitor cells with healthy mitochondria isolated from an allogeneic or syngeneic source. The Israeli company's initial clinical focus is on rare mitochondrial diseases for which there are no approved treatments, and the lead product, mnv-201, is composed of autologous hematopoietic stem cells enriched with healthy allogeneic mitochondria. Minovia Therapeutics completed an ind enabled phase i/ii clinical trial in Pearson syndrome, a fatal pediatric disease, and is planning to accelerate the clinical development for Pearson syndrome and expand the pipeline to other hematological/mitochondrial-related diseases. The company was founded in 2012 by Natalie Yivgi-Ohana, Uriel Halavee, Ephraim Aharonson, and Natalie Yivgi-Ohana has been the CEO since 2012.

BioGenCell Ltd. is an Israeli company based at Laniado Hospital in Israel that is dedicated to improving the lives of patients suffering from degenerative microvascular diseases. The company is based in Netanya, Israel. The company aims to extend its reach to address a wider range of vascular and other diseases in the future. BioGenCell has been committed to transforming the lives of patients with degenerative diseases through advanced cell therapy treatments since its inception in 2008. The company's groundbreaking tract technology uses a patient's own blood as personalized medicine. BioGenCell's personalized treatments are produced from the patients' own cells, mimicking the body's natural processes. The company was founded by Michael Belkin, Yael Porat, and Eyal Peleg, and Yael Porat has been the CEO since incorporation.

Minovia Therapeutics Ltd. is a clinical stage company based in Tirat Carmel, Israel. Minovia Therapeutics is developing a therapeutic platform called mitochondrial augmentation technology (mat) that targets the root cause of diseases generated by mitochondrial dysfunction. The platform enriches patients' hematopoietic stem and progenitor cells with healthy mitochondria isolated from an allogeneic or syngeneic source. The Israeli company's initial clinical focus is on rare mitochondrial diseases for which there are no approved treatments, and the lead product, mnv-201, is composed of autologous hematopoietic stem cells enriched with healthy allogeneic mitochondria. Minovia Therapeutics completed an ind enabled phase i/ii clinical trial in Pearson syndrome, a fatal pediatric disease, and is planning to accelerate the clinical development for Pearson syndrome and expand the pipeline to other hematological/mitochondrial-related diseases. The company was founded in 2012 by Natalie Yivgi-Ohana, Uriel Halavee, Ephraim Aharonson, and Natalie Yivgi-Ohana has been the CEO since 2012.

Minovia Therapeutics Ltd. is a clinical stage company based in Tirat Carmel, Israel. Minovia Therapeutics is developing a therapeutic platform called mitochondrial augmentation technology (mat) that targets the root cause of diseases generated by mitochondrial dysfunction. The platform enriches patients' hematopoietic stem and progenitor cells with healthy mitochondria isolated from an allogeneic or syngeneic source. The Israeli company's initial clinical focus is on rare mitochondrial diseases for which there are no approved treatments, and the lead product, mnv-201, is composed of autologous hematopoietic stem cells enriched with healthy allogeneic mitochondria. Minovia Therapeutics completed an ind enabled phase i/ii clinical trial in Pearson syndrome, a fatal pediatric disease, and is planning to accelerate the clinical development for Pearson syndrome and expand the pipeline to other hematological/mitochondrial-related diseases. The company was founded in 2012 by Natalie Yivgi-Ohana, Uriel Halavee, Ephraim Aharonson, and Natalie Yivgi-Ohana has been the CEO since 2012.

BioGenCell Ltd. is an Israeli company based at Laniado Hospital in Israel that is dedicated to improving the lives of patients suffering from degenerative microvascular diseases. The company is based in Netanya, Israel. The company aims to extend its reach to address a wider range of vascular and other diseases in the future. BioGenCell has been committed to transforming the lives of patients with degenerative diseases through advanced cell therapy treatments since its inception in 2008. The company's groundbreaking tract technology uses a patient's own blood as personalized medicine. BioGenCell's personalized treatments are produced from the patients' own cells, mimicking the body's natural processes. The company was founded by Michael Belkin, Yael Porat, and Eyal Peleg, and Yael Porat has been the CEO since incorporation.